Douglas N. Gurevitch, Barbara Armstrong, Marcos A. Piani, Michael Stewart, Petar D. Stojadinovic, Lois C. Tack, Timothy R. Walker, Andy R. Watson
Sequana Therapeutics is engaged in identifying the genes responsible for common diseases such as asthma, diabetes, osteoporosis, and others. Sequana's approach involves several distinct stages: DNA collection; genetic mapping (genotyping); physical mapping; DNA sequencing and mutation analysis; and gene characterization and assay development.
Sequana has invested heavily into using automation wherever practical. Most of the past automation has been "off-the-shelf". We are currently entering a new stage of our automation efforts by developing more complex systems in house. These projects include a custom user interface for our Packard MultiPROBE robots, a work cell for pooling PCR product based on a CRS arm and a Sagian MultiPette, a work cell for sequencing reactions also based on the CRS and Sagian, and other projects.
At this meeting I will present some of the installed and on-going efforts in automation development and system integration that are being undertaken at Sequana.
Back to Resume
Back to Home
Updated on 2/4/2009